Saturday, September 16, 2017

Randomized withdrawal design and delayed start design in area disease clinical trials

Last week at the 4th Duke-Industry Statistics Workshop, I participated in a session "Innovative clinical trial designs" organized by the UNC Professor, Dr Anastasia Ivanova.

I discussed 'randomized withdrawal design and delayed start design in rare disease clinical trials'. The presentation slides are included in the link below.

In rare disease clinical trials, we should think about more when designing the clinical trial and should

go beyond the typical, conventional RCT (randomized, controlled trials).

In the presentation, the following materials were referenced:

Randomized Withdrawal Design or Randomized Discontinuation Trial:

Monday, August 07, 2017

Another Way for Constructing Stopping Rule for Safety Monitoring of Clinical Trials

In my previous post "Constructing stopping rule for safety monitoring", I discussed the use of exact binomial confidence interval as a way to construct a stopping rule, but it was for a single arm study. 

For randomized, controlled study, the similar way can be used, but we have to calculate the exact confidence interval for the difference of two binomial proportions. We can then make a judgment if there is an excessive risk or elevated risk in the experimental arm for stopping the study for the safety reason. 

I recently read a oncology study protocol and noticed the following languages to describe the stopping criteria:  
An independent DMC will review accumulating safety data at scheduled intervals  with attention focused on the percentage of subjects with SAEs, AEs of particular concern, Grade 3 or 4 toxicities, and any Grade 5 toxicity considered at least possibly related to study treatment. Excess risk will be determined according to the lower 97.5% exact lower confidence bound on the difference between incidence rates for Group B minus Group A; a lower bound greater than 0% will be flagged as a possible reason to stop the trial. Incidence calculations will depend on the respective numerators and denominators at the time of each interim look. Wilson scores method will be used to calculate confidence limits.

To use this approach for stopping rule, we will need to calculate the exact confidence interval on a continuous basis. While Wilson scores method is mentioned for calculating the exact confidence interval, there are other methods for this calculation too.

In a paper by Will Garner (2007) Constructing Confidence Intervals for the Differences of Binomial Proportions in SAS, total 17 methods were discussed for calculating the confidence interval for two binomial proportions where a couple of methods could calculate the exact confidence interval. In SAS, proc freq can be used to calculate the exact confidence interval based on the method by Santner and Snell and the method by Chan and Zhang.

In the example below, I constructed a data set with two scenarios:
Scenario #1: 4 out of 10 patients in group A having an event and 0 out of 10 patients in group B having an event.
Scenario #2: 5 out of 10 patients in group A having an event and 0 out of 10 patients in group B having an event.

The lower bound of 95% confidence interval for scenario #1 and scenario #2 will be -0.0856 and 0.0179 respectively based on Santner-Snell exact method. Since the lower bound of 95% confidence interval for scenario #2 is greater than 0, the stopping rule for safety will be triggered.

data testdata;
 input trial treat $ x n alpha;
 1 A 4 10 0.05
 1 B 0 10 0.05
 2 A 5 10 0.05
 2 B 0 10 0.05
data testdat1;
 set testdata;
 by trial;
 if first.trial then treatn = 1;
 else treatn = 2;
 y = n - x; p = x/n; z = probit(1-alpha/2);
data testdat2a(keep=trial x y z rename=(x=x1 y=y1));
 set testdat1;
 where treatn = 1;
data testdat2b(keep=trial x y rename=(x=x2 y=y2));
 set testdat1;
 where treatn = 2;
data testdat2;
 merge testdat2a testdat2b;
 by trial;
proc transpose data = testdat1 out = x_data(rename=(_NAME_=outcome COL1=count));
 by trial treat;
 var x y;
/* Methods 1, 6 (9.4 only), 10, 12, and 13 (9.4 only) */
ods output PdiffCLs=asymp1;
proc freq data=x_data;
 by trial;
 tables treat*outcome /riskdiff (CL=(WALD MN WILSON AC HA));
 weight count;
data asymp1;
 set asymp1;
 length method $25.;
 if Type = "Agresti-Caffo" then method = "13. Agresti-Caffo";
 else if Type = "Hauck-Anderson" then method = "12. Hauck-Anderson";
 else if Type = "Miettinen-Nurminen" then method = " 6. Miettinen-Nurminen";
 else if index(Type,"Newcombe") > 0 then method = "10. Score, no CC";
 else if Type = "Wald" then method = " 1. Wald, no CC";
 keep trial method LowerCL UpperCL;

/* Method 5: MEE (9.4 only) */

ods output PdiffCLs=asymp2;
proc freq data=x_data;
 by trial;
 tables treat*outcome /riskdiff(CL=(MN(CORRECT=NO)));
 weight count;
data asymp2;
 set asymp2;
 length method $25.;
 method = " 5. Mee";
 keep trial method LowerCL UpperCL;

/* Method 3: Haldane */
data asymp3;
 set testdat2;
 by trial;
 length method $25.;
 method = " 3. Haldane";
 p1 = x1/(x1+y1);
 p2 = x2/(x2+y2);
 psi = (x1/(x1+y1) + x2/(x2+y2))/2;
 u = (1/(x1+y1) + 1/(x2+y2))/4;
 v = (1/(x1+y1) - 1/(x2+y2))/4;
 w = z/(1+z*z*u)*sqrt(u*(4*psi*(1-psi)-(p1-p2)*(p1-p2)) + 2*v*(1-2*psi)*(p1-p2) +
 theta = ((p1-p2)+z*z*v*(1-2*psi))/(1+z*z*u);
 LowerCL = max(-1,theta - w);
 UpperCL = min(1,theta + w);
 keep trial method LowerCL UpperCL;
/* Method 4: Jeffreys-Perks */
data asymp4;
 set testdat2;
 by trial;
 length method $25.;
 method = " 4. Jeffreys-Perks";
 p1 = x1/(x1+y1);
 p2 = x2/(x2+y2);
 psi = ((x1+0.5)/(x1+y1+1) + (x2+0.5)/(x2+y2+1))/2; /* Same as Haldane, but +1/2
success and failure */
 u = (1/(x1+y1) + 1/(x2+y2))/4;
 v = (1/(x1+y1) - 1/(x2+y2))/4;
 w = z/(1+z*z*u)*sqrt(u*(4*psi*(1-psi)-(p1-p2)*(p1-p2)) + 2*v*(1-2*psi)*(p1-p2) +
 theta = ((p1-p2)+z*z*v*(1-2*psi))/(1+z*z*u);
 LowerCL = max(-1,theta - w);
 UpperCL = min(1,theta + w);
 keep trial method LowerCL UpperCL;
/* Method 16: Brown and Li's Jeffreys Method */
data asymp5;
 set testdat2;
 by trial;
 length method $25.;
 method = "16. Brown-Li";
 p1 = (x1+0.5)/(x1+y1+1);
  p2 = (x2+0.5)/(x2+y2+1);
 var = p1*(1-p1)/(x1+y1) + p2*(1-p2)/(x2+y2);
 LowerCL = max(-1,(p1-p2) - z*sqrt(var));
 UpperCL = min(1,(p1-p2) + z*sqrt(var));
 keep trial method LowerCL UpperCL;
data asymp;
 set asymp1
/* Methods 2 and 11 */
ods output PdiffCLs=asymp_cc;
proc freq data=x_data;
 by trial;
 tables treat*outcome /riskdiff(correct CL=(wald wilson));
 weight count;
data asymp_cc;
 set asymp_cc;
 length method $25.;
 if index(Type,"Newcombe") > 0 then method = "11. Score, CC";
 else if index(Type,"Wald") > 0 then method = " 2. Wald, CC";
 keep trial method LowerCL UpperCL;
/* Exact methods: Methods 14 and 15 (Exact) */
ods output PdiffCLs=exact_ss;
proc freq data=x_data;
 by trial;
 tables treat*outcome /riskdiff(cl=(exact));
 weight count;
 exact riskdiff;
data exact_ss;
 set exact_ss;
 length method $25.;
 method = "14. Santner-Snell";
 keep trial method LowerCL UpperCL;

data exact;
 set exact_ss;

/* Combine all of the outputs together */
data final;
 set asymp asymp_cc exact;
/* Sort all of the outputs by trial and method */
proc sort data = final out = final;
 by trial method;

proc print data=final;
 title "Methods and 95% Confidence Interval for Difference between two rates";

Tuesday, August 01, 2017

Steroid Tapering Design Clinical Trials

In the most recent issue of New England Journal of Medicine, Stone et al published the results from "Trial of Tocilizumab in Giant-Cell Arteritis". The study used a steroid tapering design with the primary efficacy endpoint of "the rate of sustained glucocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the placebo group that underwent the 26-week prednisone taper."

There are some chronic diseases where the effective treatment is the high dose of steroid (corticosteroid, prednisone,...). To control the symptoms, the patients are usually put on the long-term use of the high dose steroid. While the steroid treatment may be effective, it can cause serious, irreversible side effects.

The list of side effects of long-term steroid use includes, but not limited to:
  • mood changes 
  • forgetfulness 
  • hair loss 
  • easy bruising 
  • a tendency toward high blood pressure and diabetes 
  • thinning of the bones (osteoporosis)
  • suppression of the adrenal glands
  • muscle weakness
  • weight gain
  • cataracts 
  • glaucoma

It will be useful to develop an alternative treatment that can replace the long-term steroid use or at least minimize the steroid dose required. To investigate the effect of the alternative treatment, clinical trial can be designed to demonstrate if the alternative treatment can taper down the steroid dose to very low or zero level while maintaining the stabilized symptoms – we call this as steroid tapering or steroid sparing design.

In a steroid tapering design, the purpose of the study is not to pursue the further improvement in disease symptoms. The steroid tapering design will have a study endpoint based on the reduction in the steroid dose while maintaining the stabilized symptoms. The possible efficacy endpoints could be the following:
  • Steroid dose reduction at Week xx from baseline
  • Percent of subjects with zero steroid dose at Week xx
  • Percent of subjects with steroid dose less than xx mg at Week xx
  • Percent of subjects with steroid dose reduction greater than and equal to 50%
  • AUC for steroid dose between week x to week y

In one of studies investigating the steroid tapering effect of IGIV in generalized myasthenia gravis, FDA confirmed during the pre-IND meeting that the treatment effect in reducing the steroid dose is meaningful.  This study is sponsored by Grifols and is currently ongoing. as indicated in, the sponsor chose "the percent of subjects with steroid dose reduction greater than and equal to 50%" as the primary efficacy endpoint. 
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
When designing a steroid tapering trial, the following issues need to be addressed:
  • Steroid tapering design has a wash-in, wash-out feature. With the effect of new treatment kicking in (if the active treatment is effective), the dose of the steroids will be reduced.
  • The purpose of the study is not the improvement in disease symptoms. The purpose is to maintain the symptoms (no deterioration) while the steroid dose is reduced. 
  • Considering the withdrawal effect of the steroid, steroid tapering design will therefore include a run-in period – the early period when the new treatment added, but steroid tapering has not started yet. To ensure the patient safety, the steroid dose tapering will only start at the end of the run-in period. During the run-in period,
  • Changes / reductions in steroid dose could influence outcomes; The treatment effect of steroid reduction must be established on the maintenance of the disease symptoms. There should be a rule to define the worsening of the clinical symptoms when the tapering must be slowed or stopped. There must be a standardized steroid tapering regimen and standardized rescue measure when disease symptoms exacerbated due to the steroid tapering.
  • Subjects who entered into the study and before the randomization should have a stable steroid dose. If the patients are not on stable steroid dose while entering the study, at the end of the study, it is not possible to tease out if the steroid dose reduction is due to the fluctuation of the steroid dose itself or due to the effect of the new treatment.
  • The stratified randomized can be used to include the baseline steroid dose category as a stratification factor to ensure that within each steroid dose category, equal number of subjects are randomized into active treatment or placebo control. Patients on higher steroid dose at baseline are more likely to have steroid dose reduction. The stratified randomization can minimize the biases due to this.
  • If the endpoint is “the mean change from baseline in steroid dose”, the magnitude of the steroid reduction between two treatment group needs to be clinically meaningful.
  • In steroid tapering design, there must be a rescue plan in the case of symptom worsening / deterioration (or exacerbation) due to the decrease in steroid dose.  
  • At the end of the study, there should be a safety follow-up period. 

There is a FDA Guidance for Industry Systemic Lupus Erythematosus — Developing Medical Products for Treatment where the steroid tapering design is proposed. 
d. Reduction in concomitant steroids Reducing corticosteroid use is an important goal in treatment of patients with SLE if it occurs in the context of a treatment that effectively controls disease activity. Therefore, for a medical product to be labeled as reducing corticosteroid usage, it should also demonstrate another clinical benefit, such as reduction in disease activity as the primary endpoint. In an add-on trial to test the steroid-sparing potential of a new medical product, patients should be enrolled during a flare and randomized to the addition of the new medical product or placebo to induction doses of corticosteroids. In both study arms, when patients achieve quiescent disease, the corticosteroid dose should be tapered to a maintenance dose that is not usually associated with major toxicities while still maintaining quiescence. The induction steroid dosage and duration of induction therapy and taper schedule should be based on the severity of disease activity in the dominant organ system involved.8 The evaluation of efficacy should be based on the proportion of patients in treatment and control groups that achieve a reduction in steroid dose to less than or equal to 10 mg per day of prednisone or equivalent, with quiescent disease and no flares (see definition above) for at least 3 consecutive months during a 1-year clinical trial. For a result to be clinically meaningful, the patient population should be on moderate to high doses of steroids at baseline. Trials should also assess the occurrence of clinically significant steroid toxicities.

The steroid tapering design can be used in various disease areas, the following examples are the application of steroid tapering design in severe refractory asthma, myasthenia gravis, systemic lupus erythmatosus, and giant cell arteritis (GCA). 

The primary measure of efficacy in our study will be the nine-month prednisone AUC (months 3–12), which measures the total prednisone doses of each patient in nine months. A reduction of prednisone AUC demonstrates that patients improved on clinical grounds so that the prednisone dose could be decreased. If the patients receiving MTX have a smaller prednisone AUC compared to the placebo patients, this will have demonstrated the efficacy of MTX. 
Based on pre-IND discussions with FDA and consultants, it was decided that the primary efficacy variable for the corticosteroid reduction study should be, for patients who were corticosteroid dependent, a reduction of the patients’ current prednisone dose to 7.5 mg/day (upper limit of physiologic levels) or less, without worsening of SLE.
The design of the steroid sparing study was a forced titration; i.e., the patient’s steroid dose at each monthly visit was to be reduced, by algorithm, if her disease activity was stable or improved. However, when a patient worsened or flared, the associated increase in corticosteroid dose, if any, required to treat the patient’s exacerbation was at the physician’s discretion and not by algorithm. The steroid reduction algorithm was based on the patient’s disease activity improving or being stable, which was defined as no change in or a decrease in SLEDAI score in comparison to her previous visit. As such, one of the issues discussed at the pre-study investigator meeting was whether patients with low SLEDAI scores, and especially those with SLEDAI scores of 0, should be enrolled into the study. There was concern that those patients with low SLEDAI scores had inactive disease, and therefore would not be affected by steroid reduction, i.e., might not be steroid dependent. However, some investigators and consultants felt that if patients were truly dependent on steroids, their low SLEDAI scores represented active disease suppressed by corticosteroids, which would worsen or flare as soon as their corticosteroids were reduced. Therefore, because there was no experience with such trials, it was decided not to exclude patients with low SLEDAI scores. The concern regarding enrollment of potentially inactive SLE patients was revisited prior to unblinding of the study. In addition it was recognized that because of the forced downward titration of steroid dose as the patients’ disease improved or remained stable, other evaluations of disease activity such as SLEDAI, etc., would not be expected to improve.
The pivotal study was designed as a double-blind, randomized, placebo-controlled, parallel group trial to evaluate GL701 100 and 200 mg/day versus placebo in female patients with mild to moderate prednisone-dependent systemic lupus erythematosus (SLE).
The study included two primary efficacy variables. The first one was responder rate. A responder was defined as a patient with the achievement of a decrease in prednisone dose to 7.5 mg/day or less sustained for no less than three consecutive scheduled visits, including the termination visit (i.e., two consecutive months), on or after Visit 7. The second primary efficacy variable was percent decrease in prednisone dose determined by comparing the prescribed prednisone (or steroid equivalent) dose at Baseline (Qualifying Visit) and the last visit prednisone dose using the physician prescribed prednisone dose recorded on the Medication Record Form.
  • Elimumab May Have Potential As A Corticosteroid-Sparing Drug When Added To Standard-Of-Care Treatment For SLE, Research Suggests.
Research suggests “the monoclonal antibody belimumab (Benlysta) may have potential as a corticosteroid-sparing drug when added to standard-of-care treatment for systemic lupus erythematosus (SLE).” Investigators found, “in pooled data from two large randomized controlled trials,” that “this blocker of B-lymphocyte stimulator was moderately associated with a higher probability of corticosteroid dose reduction and a greater average dose reduction over” one year. The findings were published in Arthritis & Rheumatology.
This paper described the design and operationalization of a blinded corticosteroid-tapering regimen for a randomized trial of tocilizumab in giant cell arteritis (GCA). The study design is sketched in the diagram below. The primary efficacy endpoint is “Proportion of patients in sustained remission at week 52 following induction and adherence to the protocol-defined prednisone taper regimen”

Monday, July 24, 2017

Excel spreadsheet to calculate the p-value for Fisher Exact test

A colleague of mine wants to have a small program to calculate the p-values during the course of the study for a randomized, open label study. For those who don't want to use any statistical software such as SAS, an excel spreadsheet can serve the purpose.

                 Calculating p-value for Fisher exact test

However, this is not a good practice and should be discouraged or prehibited. Even though this is a randomized, open label study, the study team should be restrained from continuously performing the testing based on the cumulative data.

Monday, July 10, 2017

Age Group in Pediatric, Perinatal or Preterm, and Geriatric Subjects

In a previous blog article, I discussed the “Pediatric use and geriatric use of drug and biological products”:
For Pediatric population: according to ICH guidance E11 "Clinical Investigation of Medicinal Products in the Pediatric Population", the pediatric population contains several sub-categories:
  • preterm newborn infants
  • term newborn infants (0 to 27 days)
  • infants and toddlers (28 days to 23 months)
  • children (2 to 11 years)
  • adolescents (12 to 16-18 years (dependent on region))
Notice that in FDA's guidance "General Considerations for Pediatric Pharmacokinetic Studies
for Drugs and Biological Products
for Drugs and Biological Products", the age classification is a little bit different. I am assuming that the ICH guidance E11 should be the correct reference.
Geriatric population:
Geriatric population is defined as persons 65 years of age and older. There is no upper limit of age defined.
Recently, I run into several studies where the age group needs to be further split.

Pediatric population can be further divided into 2-5 years old, 6-11 years old, and 12-16 years old.
This grouping of the pediatric population was used in a pharmacokinetic study in primary immunodeficiency patients in child. Per FDA’s request, the pediatric patients are further divided into groups 2-5, 6-11, and 12-16 years old. FDA asked that the study should contain subjects in each of the sub-groups so that the assessment can be made to see if the pharmacokinetics are consistent across different pediatric sub-groups (or at least there should be no obvious difference among these sub-groups).
An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency
The age definition in perinatal period is much trickier. In a policy statement by Committee on Fetus and Newborn “Age Terminology Duringthe Perinatal Period”, various definitions of age are described:
  • Gestational age (or “menstrual age”) is the time elapsed between the first day of the last normal
  • menstrual period and the day of delivery
  • “Chronological age” (or “postnatal” age) is the time elapsed after birth
  • Postmenstrual age (PMA) is the time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age). Postmenstrual age is usually described in number of weeks and is most frequently applied during the perinatal period beginning after the day of birth.
In clinical trials with pre-term babies, the study endpoints are usually defined based on the post-menstrual age (PMA). For example, in an article by Bassler et al “Early inhaled budesonide for the prevention ofbronchopulmonary dysplasia”, the primary outcome was a composite of death
or bronchopulmonary dysplasia at 36 weeks of postmenstrual age. While the study treatment will not be given until after the birth, 36 weeks of postmenstrual age is counted from the first day of the last menstrual period. For different babies, the chronological age or observation period (when the death or BPD event is observed) will be different depending on the actual gestational age.  

It can be illustrated in the following diagram.

  • Gestational age = birth date – the first day of the last normal menstrual period
  • Chronological age = assessment date or event date – birth date
  • Postmenstrual age = assessment date or event date – the first day of the last menstrual period
  • Postmenstrual age = gestational age + chronological age

Geriatric population can be further divided: 
In a study with Interstitial Lung Diseases (ILDs) in elderly patients, there are substantial number of patients with age >= 80 years old. The traditional definition of geriatric population using 65 years old as a cut point will not be sufficient. We end up further dividing the geriatric population into 65 - < 80 years old and >= 80 years old. We think this will provide more meaningful sub-grouping to assess the impact of the age group in ILD indication. 

Monday, July 03, 2017

(Bayes) Success Run Theorem for Sample Size Estimation in Medical Device Trial

In a recent discussion about the sample size requirement for a clinical trial in a medical device field, one of my colleagues recommended an approach of using “success run theorem” to estimate the sample size. ‘Success run theorem’ may also be called ‘Bayes success run theorem’. In process validation field, it is a typical method based on a binomial distribution that leads to a defined sample size.  

Application of success run theorem depends on the reliability of the new process (or new device). In medical device trials, the reliability is the probability that an item (i.e. the device) will carry out its function satisfactorily for the stated period when used according to the specified conditions. A reliability of 95% means that a medical device will be functional without problem for 95% of times.

With the success run theorem, we will calculate the sample size so that we have 95% confidence interval to run the device without failure (reliability). Usually, people use 95% confidence interval to achieve 95% reliability. With ‘success run theorem’, the sample size can be calculated as:

                                 N = ln(1-C)/ln( R)

Where N is the sample size needed, C is the confidence interval, and R is the reliability.

With typical 95% confidence interval to achieve 95% reliability, a sample size of 57 will be needed. An excel spreadsheet is built for calculating the sample size using success run theorem.   

The website below contains the explanation how the success run theorem formula is derived. With C = 1 – R^(n+1), we would have N = [ln(1-C)/ln(R)] – 1, slightly different from the formula above.
 How do you derive the Success-Run Theorem from the traditional form of Bayes Theorem?
This derivation above is based on uniform prior for reliability (a conservative assumption) which assumes no information from predicate devices and the same weight to every reliability value to fall anywhere between 0 to 1.

In medical device field, devices evolve and they are constantly being improved. When we evaluate a new device or next generation device, there is usually some prior information that can be based on. Therefore, instead of uniform prior for reliability, Bayesian technique with mixture of beta priors for reliability can be applied. Using mixtures of beta priors for reliability, we will be able to incorporate historical information from predicate device to decrease the sample size requirement.

We have seen this application in the field of automotive electronics attribute testing, but have not seen any application in FDA regulatory medical device testing.


Saturday, June 17, 2017

Statistical Analysis Plan in Clinical Trial Registries

Recently, a question comes up when I search the – the EU clinical trial registry website – the counterpart of in US. Should the clinical trial registries include the statistical analysis plan (for primary and secondary efficacy endpoints)? The statistical analysis plan could include the statistical methods for primary and secondary endpoints, missing data handling, stopping rule for early termination of the study, justification for sample size estimation, and so on.
For in US, Protocol Registration Data Element Definitions for Interventional and Observational Studies requires the inclusion of some details about statistical analyses:
Detailed Description Definition:
Extended description of the protocol, including more technical information (as compared to the Brief Summary), if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as Eligibility Criteria or outcome measures. Limit: 32,000 characters. 
For Patient Registries: Also describe the applicable registry procedures and other quality factors (for example, third party certification, on-site audit). In particular, summarize any procedures implemented as part of the patient registry, including, but not limited to the following: 
  • Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.
  • Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
  • Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (for example, medical records, paper or electronic case report forms, or interactive voice response systems).
  • Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information if used (for example, World Health Organization Drug Dictionary, MedDRA), and normal ranges if relevant.
  • Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.
  • Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.
  • Plan for missing data to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.
  • Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan. 
In EU, the is mainly based on the EudraCT database. As part of the clinical trial application (similar to IND in US), the sponsor needs to provide the clinical trial protocol information to be entered into EudraCT database.

In the guidance “Detailed guidance on the European clinical trials database (EUDRACT Database)”, it asks for the information regarding the clinical trial design, but there is no mention of the statistical analysis plan.

As a matter of fact, all clinical trial registries across different countries are supposed to meet the requirements by International Clinical Trials Registry Platform (ICTRP) from World Health Organization. In the list of elements for WHO Trial Registration Data Set , there is no mention of statistical analysis plan as part of the registration elements.

No matter what, there seems to be different understanding about the details of the clinical trial to be posted in clinical trial registries. Some companies posted very detail information including how the clinical trial data would be analyzed. Other companies were very restraint and posted as little information as possible.

In terms of the elements regarding the statistical analyses, there are actual more studies in with some details than studies in even though the requirement regarding the inclusion of the statistical analysis plan is mentioned in, not in For example, in a study “A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib”, a lot of details about the statistical analyses are provided in the

When I try to see if the interim analysis and its corresponding boundary method are mentioned in, I can clearly see the inconsistencies across different trial sponsors.

Here are some studies that the interim analysis and boundary method are mentioned.
Here are some studies that the interim analysis is mentioned, but the boundary method is not.